 - Determine whether the addition of bevacizumab to the docetaxelanthracycline-based regimens docetaxel with AC, docetaxel and capecitabine with AC, and docetaxel and gemcitabine hydrochloride with AC will increase the rate of pCR of the breast and nodes compared to the same docetaxelanthracycline-based regimens without bevacizumab in these patients. 